Glioblastoma (GBM) remains one of the most aggressive and lethal primary brain tumors in adults, largely due to its profound intratumoral heterogeneity. This variability poses a major challenge to developing effective therapies that can address diverse tumor subpopulations. Despite advances in understanding GBM biology, strategies that precisely target this heterogeneity have been limited.
On September 30, 2025, collaborative research teams from the Medical Research Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University (Guangzhou, China), and the Center for Stem Cell Biology and Tissue Engineering, Key Laboratory for Stem Cells and Tissue Engineering, Ministry of Education, Sun Yat-sen University (Guangzhou, China), published a landmark study in the prestigious journal Nature Cell Biology (Impact Factor: 19.1).
The paper, titled “Defining heterogeneity in core regulatory circuitry reveals HOXB3 condensation as a potential target in glioblastoma”, uncovers a novel layer of GBM heterogeneity at the level of core regulatory circuitry (CRC) and identifies HOXB3 condensation as a key driver of specific tumor phenotypes.
Key Discoveries and Innovations
Using single-cell CUT&Tag profiling of H3K27ac modifications, the team mapped pronounced heterogeneity within the CRC of GBM cells. They discovered that CRC transcription factors, particularly HOXB3, exhibit heterogeneous condensation states shaped by its intrinsically disordered regions (IDRs) and physical interactions with RUNX1. These condensates directly influence chromatin organization and drive oncogenic transcriptional programs in distinct GBM subpopulations.
Building on this mechanistic insight, the researchers designed and synthesized a peptide inhibitor, P621-R9, that specifically disrupts HOXB3 condensate formation. Treatment with P621-R9:
- Altered chromatin accessibility at super-enhancer-associated oncogenic loci
- Suppressed transcription of downstream target genes
- Selectively reduced tumorigenic potential in GBM cells and patient-derived xenograft (PDX) models that displayed HOXB3 condensation
Importantly, P621-R9 showed no significant effect in PDX models lacking HOXB3 condensates, demonstrating remarkable subpopulation specificity and highlighting its potential as a precision therapeutic agent.
Why This Study Matters
This work represents a major advance in several ways:
- First comprehensive single-cell view of CRC heterogeneity in GBM
- Identification of phase separation/condensation of HOXB3 as a previously unrecognized driver of tumor phenotypic diversity
- Proof-of-concept for peptide-based targeting of condensate-forming transcription factors
- Subpopulation-selective efficacy, aligning with the principles of precision oncology for heterogeneous cancers
By linking biomolecular condensates to GBM heterogeneity and demonstrating targeted disruption, the study opens a promising new avenue for developing therapies against specific GBM subtypes, potentially improving outcomes in this devastating disease.
Key Reagent Supplied by SBS Genetech
The truncation mutants and point mutants used in this study were generated using a site-directed mutagenesis kit provided by SBS Genetech, following the manufacturer’s instructions.
Since 2000, SBS Genetech has been committed to delivering safer, higher-quality, and more cost-effective molecular biology tools to researchers worldwide. Our products support leading teams in over 60 countries and are routinely cited in top-tier journals including Science, Cell, Nature series, Cancer Cell, and more.
We are proud to have contributed to this groundbreaking research and extend our heartfelt congratulations to the entire team on this outstanding achievement published in Nature Cell Biology.
We believe that continued innovation will enable SBS Genetech to further empower discoveries in tumor biology, condensate-targeted therapies, and precision medicine for aggressive cancers like glioblastoma.
We look forward to seeing how condensate-disrupting strategies like P621-R9 evolve into clinical candidates and bring new hope to GBM patients.